These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 6736273)

  • 1. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients.
    Ereshefsky L; Davis CM; Harrington CA; Jann MW; Browning JL; Saklad SR; Burch NR
    J Clin Psychopharmacol; 1984 Jun; 4(3):138-42. PubMed ID: 6736273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients.
    Louza Neto MR; Müller-Spahn F; Rüther E; Scherer J
    Pharmacopsychiatry; 1988 Sep; 21(5):226-31. PubMed ID: 3227054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haloperidol plasma and red blood cell levels and clinical antipsychotic response.
    Garver DL; Hirschowitz J; Glicksteen GA; Kanter DR; Mavroidis ML
    J Clin Psychopharmacol; 1984 Jun; 4(3):133-7. PubMed ID: 6736272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma reduced haloperidol/haloperidol ratios in schizophrenic patients treated with high dosages of haloperidol.
    Chang WH; Shieh YS; Liu HC; Jann MW; Chien CP
    Eur Neuropsychopharmacol; 1994 Jun; 4(2):119-26. PubMed ID: 7919941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haloperidol: therapeutic window in schizophrenia.
    Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
    J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients.
    Yasui-Furukori N; Kondo T; Mihara K; Suzuki A; Inoue Y; Kaneko S
    J Clin Psychopharmacol; 2003 Oct; 23(5):435-40. PubMed ID: 14520118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroleptic radioreceptor activity and clinical outcome in schizophrenia.
    Contreras S; Alexander H; Faber R; Bowden C
    J Clin Psychopharmacol; 1987 Apr; 7(2):95-8. PubMed ID: 3584527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced haloperidol/haloperidol ratios after oral haloperidol and decanoate administration in schizophrenics.
    Chang WH; Lin SK; Juang DJ; Chen LC; Yang CH; Hu WH; Chien CP; Lam YF; Jann MW
    Prog Neuropsychopharmacol Biol Psychiatry; 1993 Jan; 17(1):105-12. PubMed ID: 8416597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood levels of haloperidol in schizophrenic patients.
    Shvartsburd A; Dekirmenjian H; Smith RC
    J Clin Psychopharmacol; 1983 Feb; 3(1):7-12. PubMed ID: 6833528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haloperidol decanoate pharmacokinetics in red blood cells and plasma.
    Dysken MW; Kim SW; Vatassery G; Johnson SB; Skare S; Holden L; Thomsyck L
    J Clin Psychopharmacol; 1992 Apr; 12(2):128-32. PubMed ID: 1573034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study.
    McEvoy JP; Stiller RL; Farr R
    J Clin Psychopharmacol; 1986 Jun; 6(3):133-8. PubMed ID: 3711363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood levels of haloperidol and clinical outcome in schizophrenia.
    Doddi S; Rifkin A; Karajgi B; Cooper T; Borenstein M
    J Clin Psychopharmacol; 1994 Jun; 14(3):187-95. PubMed ID: 8027415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with haloperidol and orphenadrine in schizophrenia. A clinical and pharmacokinetic study.
    Altamura AC; Buccio M; Colombo G; Terzi A; Cazzullo CL
    Encephale; 1986; 12(1):31-6. PubMed ID: 3698889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum haloperidol and neuroleptic receptor levels in chronic psychosis.
    Cannon DJ; McMillan DE; Newton JE; Fody EP; Metzer WS; Claybrook M; Couch L; Paige SR
    Ann Clin Lab Sci; 1988; 18(5):378-83. PubMed ID: 3178137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Standard and high doses of haloperidol. Clinical, pharmacokinetic and pharmacodynamic aspects].
    Schilkrut R; Haverbeck C; Duran E; Delgado S; Kohen P; Birkner R; Katz I
    Acta Psiquiatr Psicol Am Lat; 1981; 27(4-5):315-24. PubMed ID: 7348089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables.
    Lane HY; Chang WH; Chang YC; Hu OY; Lin HN; Jann MW; Hu WH
    Psychiatry Res; 1997 Sep; 72(2):127-32. PubMed ID: 9335203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study].
    Scatton B; Zarifian E; Bianchetti G; Cuche H; Loo H; Morselli PL
    Encephale; 1982; 8(1):1-8. PubMed ID: 7094868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketone reductase activity and reduced haloperidol/haloperidol ratios in haloperidol-treated schizophrenic patients.
    Huang HF; Jann MW; Tseng YT; Chung MC; Chien CP; Chang WH
    Psychiatry Res; 1995 Jul; 57(2):101-8. PubMed ID: 7480377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.